Common SGLT-2 Inhibitors
The five commercially available SGLT-2 inhibitors are: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin 1, 2.
Available Agents
These medications, also known as the "gliflozin class," work by inhibiting the SGLT-2 cotransporter in the proximal renal tubules, thereby reducing glucose and sodium reabsorption and promoting urinary glucose excretion 1.
The Five SGLT-2 Inhibitors:
- Canagliflozin
- Dapagliflozin
- Empagliflozin
- Ertugliflozin
- Sotagliflozin
All five agents are FDA-approved and share similar mechanisms of action, though they differ in their specific pharmacokinetic properties and approved indications 2, 3.
Current Clinical Applications
These agents have evolved far beyond simple glucose-lowering medications. Current guidelines now recommend SGLT-2 inhibitors as foundational therapy across multiple conditions 4, 5:
Primary Indications:
- Chronic kidney disease (with or without diabetes) when eGFR ≥20 mL/min/1.73 m² 4, 5
- Heart failure (HFrEF, HFmrEF, and HFpEF) regardless of diabetes status 5
- Type 2 diabetes with high cardiovascular risk or established atherosclerotic cardiovascular disease 5
- Cardiovascular-kidney-metabolic syndrome as part of integrated management 5
The 2024 BMJ guidelines represent a paradigm shift, recommending SGLT-2 inhibitors broadly for adults with CKD irrespective of diabetes status, moving beyond the previous restriction to only diabetic patients 4.